NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

SeaStar Medical Holding Corporation (ICU) Stock Analysis

SeaStar Medical Holding Corporation (ICU) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ICU

$3.17

+$0.12 (+3.93%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ICU with… →

ICU Key Statistics

As of Oct 21, 2026
Trading
Open
$3.09
Previous Close
$3.05
Day's Range
3.04–3.18
52-Week Range
2.07–6.48
Volume
80.62K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.07
Valuation
Market Cap
$16.68M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.74
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.97
Financials (FY)
Revenue (FY)
$1.23M+814.07%
Net Income (FY)
−$12.15M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.26M
1-Year Return
−49.68%
Dividend and dates
Avg Volume
113.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ICU closed at $3.17, −49.68% over 1 year.

SeaStar Medical Holding Corporation (ICU) has a market capitalization of $16.68M.

In fiscal 2025, ICU reported revenue of $1.23M.

ICU Stock Return by Calendar Year

SeaStar Medical Holding Corporation (ICU) return since Mar 2021: what $10,000 became

1 year
$10,000 $5,032
−49.68%
5 years
$10,000 $13
−99.87%
Since Mar 2021
$10,000 $13
−99.87%

If you had invested $10,000 in SeaStar Medical Holding Corporation (ICU) at the close on March 18, 2021, the earliest close on record here, it would have been worth $13 at the close on October 21, 2026: −99.87% in total, −69.54% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+32.08%
2025−87.63%
2024−82.48%
2023−89.20%
2022−59.16%
2021 (partial year)+2.45%

As of October 21, 2026.

ICU Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.23M−$12.15M−984.6%
2024$135.00K−$24.83M−18,392.6%
2023$0.00−$26.23M—
2022$0.00−$12.19M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.23M$1.18M−$12.18M−$12.15M−984.6%
2024$135.00K$135.00K−$17.84M−$24.83M−18,392.6%
2023$0.00$0.00−$14.21M−$26.23M—
2022$0.00—−$11.61M−$12.19M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ICU Valuation vs Biotechnology Median

Median of 608 stocks
MetricICUBiotechnology medianvs median
P/S ratio9.7413.3027% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values SeaStar Medical Holding Corporation (ICU) at $16.68M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 18.

ICU last closed at $3.17 on October 21, 2026. That is +$0.12 (+3.93%) against the previous close. Over the past 52 weeks the price has ranged from $2.07 to $6.48. The latest close sits 53.14% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.23M. That is +814.07% against the prior fiscal year, when revenue was $135.00K. The same year closed with a net loss of $12.15M. Trailing earnings per share are −2.97.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $1.23M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 9.74 times revenue. On price-to-sales that is 26.79% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −49.68%. Measured over 5 years, that is −73.65% a year compounded. Beta against the wider market is reported at −1.07. Daily returns over the trailing 5 years annualize to a volatility of 133.5%.

Growth & Income

No dividend is on file for ICU.

2026 is still running; the total return is +32.08% year to date. The strongest complete calendar year on file is 2022 at −59.16%; the weakest is 2023 at −89.20%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

SeaStar Medical Holding Corporation (ICU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
SeaStar Medical Holding Corporation ICU $16.68M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. SeaStar Medical Holding Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

Visit website →